Skip to main content

Table 8 Univariate and multivariate model of variables associated with ADR

From: Incidence of adverse reaction of drugs used in COVID-19 management: a retrospective, observational study

Variable Crude OR (95% CI) P value Adjusted OR (95% CI)a P value
Demographics
 Age (mean ± SD in years) 1.03 (1.02, 1.04) < 0.001
 Sex
      Male 1 1
      Female 1.28 (0.94, 1.75) 0.117 1.53 (1.06, 2.20) 0.024
Clinical background
 History of drug allergy
      Yes 0.76 (0.29, 2.00) 0.577
      No 1 1
 Presence of comorbidity
      Yes 2.26 (1.68, 3.06) < 0.001
      No 1 1
 COVID-19 category
      Patient under investigation 1 1
      Stage 1 0.25 (0.03, 2.08) 0.202
      Stage 2 0.67 (0.30, 1.48) 0.319
      Stage 3 2.45 (1.18, 5.07) 0.016 2.58 (1.20, 5.55) 0.015
      Stage 4 12.11 (5.62, 26.10) < 0.001 4.17 (1.79, 9.73) 0.001
      Stage 5 6.47 (2.52, 16.60) < 0.001
 Number of COVID-19 drug(s) 3.94 (3.20, 4.85) < 0.001 3.34 (2.51, 4.44) < 0.001
  1. aForward and backward LR applied. Hosmer and Lemeshow = 0.121. Classification table = 83.2. No multicollinearity was detected. ROC = 0.83 (0.79, 0.86; P value ≤ 0.001). Only variables with P value < 0.05 were mentioned in the AOR